肝癌药物市场－全球产业规模、份额、趋势、机会及预测（依癌症类型、器材、年龄、病因、给药途径、通路、地区及竞争格局划分，2021-2031年）

全球肝癌治疗市场预计将从2025年的41.1亿美元成长到2031年的69.4亿美元，复合年增长率（CAGR）为9.12%。该市场涵盖多种药物干预措施，包括标靶治疗、免疫疗法和化疗药物，旨在治疗肝细胞癌和肝内胆管癌。推动市场成长的关键因素包括全球慢性B型和C型肝炎发病率的上升，以及与METABOLIC INC.症候群相关的非酒精性脂肪肝盛行率的增加。此外，不断上涨的医疗保健成本和人口老化也支撑了对先进临床解决方案的强劲需求，确保市场成长超越短期趋势。

然而，创新生物疗法和联合治疗的高昂成本严重阻碍了市场成长，限制了患者的治疗机会，尤其是在开发中国家。晚期诊断的高发生率进一步加剧了这一经济挑战，限制了治疗性介入的效用，并给医疗预算带来了巨大压力。根据美国癌症协会预测，到2024年，全球将有超过70万人死于肝癌。这项数据凸显了开发经济有效的治疗方法以应对该疾病高死亡率的迫切需求。

市场驱动因素

市场扩张的根本驱动力在于慢性B型和C型肝炎病毒感染带来的巨大负担，这两种病毒感染是全球肝细胞癌的主要原因。随着慢性病毒性肝炎进展为肝硬化和恶性肿瘤，需要持续长期管理和药物干预，这直接推动了对病毒和抗肿瘤治疗的需求。世界卫生组织（世卫组织）于2024年4月发布的《2024年世界肝炎报告》显示，到2022年，全球将有约2.54亿慢性乙型肝炎患者和5000万慢性丙型肝炎患者，这凸显了庞大的患者群体需要疾病修正治疗和后续观察。

同时，新型免疫疗法和联合治疗的加速应用正在重塑该领域，这些疗法已显着超越传统全身疗法，成为不可切除疾病的标准治疗方案。製药公司正积极将能够延长患者生存期的查核点抑制剂商业化，其在已开发市场的应用也迅速成长。例如，Astra Zeneca在2024年11月发布的「2024年第三季财报」中报告称，其免疫疗法Imfinzi的第三季销售额达到16亿美元，较去年同期增长31%，这主要得益于肿瘤领域的需求增长。生物製药使用量的激增与癌症诊断率的持续上升相吻合。根据美国癌症协会发布的《2024年癌症事实与数据》，预计2024年美国将新增41,630例肝癌和肝内胆管癌病例，凸显了对这些先进治疗方法的迫切需求。

市场挑战

生物製药和联合治疗带来的巨大经济负担是全球肝癌治疗市场的主要阻碍因素。高昂的药物研发和生产成本最终会推高终端使用者的治疗费用，限制病患的用药途径，尤其是在医疗报销体系薄弱的发展中地区。当价格超出公共卫生预算和患者的负担能力时，治疗方法的普及率会显着下降。这种经济障碍阻碍了临床解决方案的广泛应用，最终减少了生产商的潜在收入来源，并抑制了市场扩张。

高昂的单次治疗费用以及疾病的高发生率加剧了这项挑战。市场面临高发病率带来的高需求与大规模治疗经济可行性低之间的权衡。根据美国癌症协会估计，2024年美国将新增约41,630例肝癌病例。使用昂贵的治疗药物治疗如此多的患者，累积费用将给保险公司和国家医疗保健系统带来沉重负担。因此，支付方通常会实施严格的报销标准，这限制了潜在市场规模，并阻碍了整个产业的成长。

市场趋势

局部治疗与全身性治疗的融合正在迅速改变肝细胞癌（HCC）的治疗格局，尤其对于传统上仅采用导管介入治疗的过渡时期HCC患者而言更是如此。这一趋势是将全身性免疫疗法与经动脉化疗栓塞术（TACE）直接整合，以降低单纯栓塞治疗的高復发率。透过在治疗早期引入生物製药，临床医生旨在靶向微转移病灶并改善长期疗效。根据2025年1月《柳叶刀》杂誌报道，EMERALD-1试验结果显示，Durvalumab、Bevacizumab联合治疗TACE治疗的中位无恶化生存期达到15.0个月，与标准TACE通讯协定相比，疗效具有统计学意义的显着改善，有效扩大了先进治疗方法的应用范围。

同时，新一代口服蛋白酪氨酸激酶抑制剂（TKI）市场正在经历復兴和发展，尤其是在新型联合治疗策略方面，其疗效树立了新的标竿。与传统的全身性治疗不同，这些现代小分子抑制剂与查核点抑制剂合併使用时，能够显着延长患者的存活期，突破传统临床治疗在不可切除疾病中的限制。这一趋势凸显了激酶抑制剂作为治疗平台的重要性。根据《美国临床肿瘤学会邮报》（The ASCO Post）2025年10月报道，在CARES-310试验的最终分析中，蛋白酪氨酸激酶抑製剂利沃塞拉尼（rivocelanib）与卡瑞利珠单抗（camrelizumab）的联合治疗治疗方法显示出23.8个月的中位总生存期。这是目前国际III期临床试验中针对此适应症通报的最长总存活期，进一步证实了标靶口服药物的重新运作。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球肝癌治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依癌症类型（肝细胞癌、胆管癌、肝转移瘤、肝母细胞瘤、血管肉瘤）
  • 治疗方法（标靶治疗、放射线治疗和化疗、免疫治疗、其他）
  • 透过设备（电脑放射成像、磁振造影、超音波、其他）
  • 依年龄划分（0-18岁、18-35岁、35-50岁、50岁以上）
  • 依病因分类（非酒精性脂肪肝、肝硬化、肝臟过度消耗、其他）
  • 给药途径（口服、静脉注射、其他）
  • 通路（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美肝癌药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲肝癌药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章 亚太地区肝癌药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲肝癌药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲肝癌药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球肝癌药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Bayer AG
• Bristol Myers Squibb
• Merck & Co., Inc.
• Exelixis, Inc.
• Eisai Co., Ltd.
• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• Eli Lilly and Company
• Novartis AG
• AstraZeneca PLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Liver Cancer Therapeutics Market is projected to expand from USD 4.11 Billion in 2025 to USD 6.94 Billion by 2031, reflecting a CAGR of 9.12%. This market encompasses pharmacological interventions, including targeted therapies, immunotherapies, and chemotherapeutic agents, designed to treat hepatocellular carcinoma and intrahepatic bile duct cancers. Growth is primarily driven by the rising global incidence of chronic Hepatitis B and C infections, along with the increasing prevalence of non-alcoholic fatty liver disease linked to metabolic syndromes. Furthermore, increased healthcare expenditure and an aging population are supporting robust demand for advanced clinical solutions, ensuring growth beyond temporary trends.

Conversely, the substantial costs associated with innovative biologic treatments and combination regimens present a major obstacle to market growth, restricting patient access particularly in developing economies. This economic challenge is compounded by the high frequency of late-stage diagnoses, which limits the utility of curative interventions and strains healthcare budgets. According to the American Cancer Society, liver cancer caused over 700,000 deaths globally in 2024. This statistic highlights the urgent necessity for cost-effective therapeutic advancements to address the high mortality rates associated with the disease.

Market Driver

The market's expansion is fundamentally propelled by the significant burden of chronic Hepatitis B and C viral infections, which act as the leading causes of hepatocellular carcinoma worldwide. As chronic viral hepatitis progresses to liver cirrhosis and malignancy, it creates a continuous need for long-term management and pharmacological intervention, directly driving the demand for antiviral and antineoplastic treatments. According to the World Health Organization's 'Global Hepatitis Report 2024' released in April 2024, approximately 254 million people were living with chronic hepatitis B and 50 million with hepatitis C globally in 2022, underscoring the vast population requiring disease-modifying therapies and surveillance.

Simultaneously, the sector is being reshaped by the accelerated adoption of novel immunotherapy and combination regimens, which have largely superseded older systemic agents as the standard of care for unresectable disease. Pharmaceutical developers are actively commercializing checkpoint inhibitors that offer superior survival rates, leading to rapid uptake in developed economies. For instance, AstraZeneca reported in its 'Q3 2024 Results' in November 2024 that the immunotherapy agent Imfinzi generated $1.6 billion in sales in the third quarter alone, a 31% year-over-year increase driven by oncology demand. This surge in biologic utilization coincides with persistent diagnostic rates; the American Cancer Society's 'Cancer Facts & Figures 2024' projected 41,630 new cases of liver and intrahepatic bile duct cancer in the US for the year, reinforcing the critical need for these advanced options.

Market Challenge

The significant financial burden associated with biologic treatments and combination regimens serves as a primary restraint on the global liver cancer therapeutics market. High drug development and manufacturing expenses result in elevated pricing for end users, which limits patient access, particularly in developing regions with inadequate healthcare reimbursement frameworks. When pharmacological interventions are priced beyond the reach of public health budgets and individual patients, adoption rates slow considerably. This economic barrier prevents the widespread utilization of clinical solutions, thereby reducing potential revenue streams for manufacturers and stalling market expansion.

This challenge is further compounded when the high cost per patient is multiplied by the significant prevalence of the disease. The market faces a dichotomy where demand is robust due to incidence rates, yet the economic feasibility for widespread treatment remains low. According to the American Cancer Society, an estimated 41,630 new cases of liver cancer were diagnosed in the United States in 2024. The cumulative cost required to treat such a volume of patients with premium-priced therapeutics places immense pressure on insurance providers and national health systems. Consequently, payers often implement strict reimbursement criteria, which limits the addressable market size and hampers the overall growth trajectory of the industry.

Market Trends

The Convergence of Locoregional and Systemic Therapies is rapidly transforming the treatment landscape, specifically for patients with intermediate-stage hepatocellular carcinoma who were historically managed with catheter-based interventions alone. This trend involves the integration of systemic immunotherapies directly with transarterial chemoembolization (TACE) to reduce the high rates of disease recurrence associated with embolization monotherapy. By introducing biologic agents earlier in the treatment continuum, clinicians aim to target micrometastatic disease and improve long-term outcomes. According to The Lancet in January 2025, the 'EMERALD-1 study results' showed that the combination of durvalumab, bevacizumab, and TACE achieved a median progression-free survival of 15.0 months, a statistically significant improvement over the standard TACE protocol, effectively expanding the utilization of advanced therapeutics.

Simultaneously, the market is witnessing the resurgence and evolution of Next-Generation Oral Tyrosine Kinase Inhibitors (TKIs), which are establishing new efficacy benchmarks particularly when utilized in novel combination strategies. Unlike legacy systemic agents, these modern small molecule inhibitors are being paired with checkpoint inhibitors to deliver extended survival benefits that challenge historical clinical ceilings in unresectable disease. This trend highlights the continued relevance of kinase inhibitors as a cornerstone of therapy. According to The ASCO Post in October 2025, the 'CARES-310 trial final analysis' reported that the combination of the tyrosine kinase inhibitor rivoceranib and camrelizumab demonstrated a median overall survival of 23.8 months, the longest duration reported for any treatment in a global Phase 3 study for this indication, underscoring the revitalized role of targeted oral agents.

Key Market Players

• Bayer AG
• Bristol Myers Squibb
• Merck & Co., Inc.
• Exelixis, Inc.
• Eisai Co., Ltd.
• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• Eli Lilly and Company
• Novartis AG
• AstraZeneca PLC

Report Scope

In this report, the Global Liver Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Liver Cancer Therapeutics Market, By Cancer Type

• Hepatocellular Carcinoma
• Cholangiocarcinoma
• Liver Metastasis
• Hepatoblastoma
• Angiosarcoma

Liver Cancer Therapeutics Market, By Therapy

• Targeted Therapy
• Radiation and Chemotherapy Therapy
• Immunotherapy
• Others

Liver Cancer Therapeutics Market, By Equipment

• Computed Radiography
• MRI
• Sonography
• Others

Liver Cancer Therapeutics Market, By Age

• 0-18
• 18-35
• 35-50
• 50+

Liver Cancer Therapeutics Market, By Factors

• Non-Alcoholic Fatty Liver Disease
• Cirrhosis
• Excessive Liver Consumption
• Others

Liver Cancer Therapeutics Market, By Route of Administration

• Oral
• Intra-Venous
• Others

Liver Cancer Therapeutics Market, By Distribution channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Liver Cancer Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Liver Cancer Therapeutics Market.

Available Customizations:

Global Liver Cancer Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Liver Cancer Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Type (Hepatocellular Carcinoma, Cholangiocarcinoma, Liver Metastasis, Hepatoblastoma, Angiosarcoma)
  • 5.2.2. By Therapy (Targeted Therapy, Radiation and Chemotherapy Therapy, Immunotherapy, Others)
  • 5.2.3. By Equipment (Computed Radiography, MRI, Sonography, Others)
  • 5.2.4. By Age (0-18, 18-35, 35-50, 50+)
  • 5.2.5. By Factors (Non-Alcoholic Fatty Liver Disease, Cirrhosis, Excessive Liver Consumption, Others)
  • 5.2.6. By Route of Administration (Oral, Intra-Venous, Others)
  • 5.2.7. By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.8. By Region
  • 5.2.9. By Company (2025)
• 5.3. Market Map

6. North America Liver Cancer Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Type
  • 6.2.2. By Therapy
  • 6.2.3. By Equipment
  • 6.2.4. By Age
  • 6.2.5. By Factors
  • 6.2.6. By Route of Administration
  • 6.2.7. By Distribution channel
  • 6.2.8. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Liver Cancer Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Type
      • 6.3.1.2.2. By Therapy
      • 6.3.1.2.3. By Equipment
      • 6.3.1.2.4. By Age
      • 6.3.1.2.5. By Factors
      • 6.3.1.2.6. By Route of Administration
      • 6.3.1.2.7. By Distribution channel
  • 6.3.2. Canada Liver Cancer Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Type
      • 6.3.2.2.2. By Therapy
      • 6.3.2.2.3. By Equipment
      • 6.3.2.2.4. By Age
      • 6.3.2.2.5. By Factors
      • 6.3.2.2.6. By Route of Administration
      • 6.3.2.2.7. By Distribution channel
  • 6.3.3. Mexico Liver Cancer Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Type
      • 6.3.3.2.2. By Therapy
      • 6.3.3.2.3. By Equipment
      • 6.3.3.2.4. By Age
      • 6.3.3.2.5. By Factors
      • 6.3.3.2.6. By Route of Administration
      • 6.3.3.2.7. By Distribution channel

7. Europe Liver Cancer Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Type
  • 7.2.2. By Therapy
  • 7.2.3. By Equipment
  • 7.2.4. By Age
  • 7.2.5. By Factors
  • 7.2.6. By Route of Administration
  • 7.2.7. By Distribution channel
  • 7.2.8. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Liver Cancer Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Type
      • 7.3.1.2.2. By Therapy
      • 7.3.1.2.3. By Equipment
      • 7.3.1.2.4. By Age
      • 7.3.1.2.5. By Factors
      • 7.3.1.2.6. By Route of Administration
      • 7.3.1.2.7. By Distribution channel
  • 7.3.2. France Liver Cancer Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Type
      • 7.3.2.2.2. By Therapy
      • 7.3.2.2.3. By Equipment
      • 7.3.2.2.4. By Age
      • 7.3.2.2.5. By Factors
      • 7.3.2.2.6. By Route of Administration
      • 7.3.2.2.7. By Distribution channel
  • 7.3.3. United Kingdom Liver Cancer Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Type
      • 7.3.3.2.2. By Therapy
      • 7.3.3.2.3. By Equipment
      • 7.3.3.2.4. By Age
      • 7.3.3.2.5. By Factors
      • 7.3.3.2.6. By Route of Administration
      • 7.3.3.2.7. By Distribution channel
  • 7.3.4. Italy Liver Cancer Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cancer Type
      • 7.3.4.2.2. By Therapy
      • 7.3.4.2.3. By Equipment
      • 7.3.4.2.4. By Age
      • 7.3.4.2.5. By Factors
      • 7.3.4.2.6. By Route of Administration
      • 7.3.4.2.7. By Distribution channel
  • 7.3.5. Spain Liver Cancer Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cancer Type
      • 7.3.5.2.2. By Therapy
      • 7.3.5.2.3. By Equipment
      • 7.3.5.2.4. By Age
      • 7.3.5.2.5. By Factors
      • 7.3.5.2.6. By Route of Administration
      • 7.3.5.2.7. By Distribution channel

8. Asia Pacific Liver Cancer Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Type
  • 8.2.2. By Therapy
  • 8.2.3. By Equipment
  • 8.2.4. By Age
  • 8.2.5. By Factors
  • 8.2.6. By Route of Administration
  • 8.2.7. By Distribution channel
  • 8.2.8. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Liver Cancer Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Type
      • 8.3.1.2.2. By Therapy
      • 8.3.1.2.3. By Equipment
      • 8.3.1.2.4. By Age
      • 8.3.1.2.5. By Factors
      • 8.3.1.2.6. By Route of Administration
      • 8.3.1.2.7. By Distribution channel
  • 8.3.2. India Liver Cancer Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Type
      • 8.3.2.2.2. By Therapy
      • 8.3.2.2.3. By Equipment
      • 8.3.2.2.4. By Age
      • 8.3.2.2.5. By Factors
      • 8.3.2.2.6. By Route of Administration
      • 8.3.2.2.7. By Distribution channel
  • 8.3.3. Japan Liver Cancer Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Type
      • 8.3.3.2.2. By Therapy
      • 8.3.3.2.3. By Equipment
      • 8.3.3.2.4. By Age
      • 8.3.3.2.5. By Factors
      • 8.3.3.2.6. By Route of Administration
      • 8.3.3.2.7. By Distribution channel
  • 8.3.4. South Korea Liver Cancer Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Cancer Type
      • 8.3.4.2.2. By Therapy
      • 8.3.4.2.3. By Equipment
      • 8.3.4.2.4. By Age
      • 8.3.4.2.5. By Factors
      • 8.3.4.2.6. By Route of Administration
      • 8.3.4.2.7. By Distribution channel
  • 8.3.5. Australia Liver Cancer Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Cancer Type
      • 8.3.5.2.2. By Therapy
      • 8.3.5.2.3. By Equipment
      • 8.3.5.2.4. By Age
      • 8.3.5.2.5. By Factors
      • 8.3.5.2.6. By Route of Administration
      • 8.3.5.2.7. By Distribution channel

9. Middle East & Africa Liver Cancer Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Type
  • 9.2.2. By Therapy
  • 9.2.3. By Equipment
  • 9.2.4. By Age
  • 9.2.5. By Factors
  • 9.2.6. By Route of Administration
  • 9.2.7. By Distribution channel
  • 9.2.8. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Liver Cancer Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Type
      • 9.3.1.2.2. By Therapy
      • 9.3.1.2.3. By Equipment
      • 9.3.1.2.4. By Age
      • 9.3.1.2.5. By Factors
      • 9.3.1.2.6. By Route of Administration
      • 9.3.1.2.7. By Distribution channel
  • 9.3.2. UAE Liver Cancer Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Type
      • 9.3.2.2.2. By Therapy
      • 9.3.2.2.3. By Equipment
      • 9.3.2.2.4. By Age
      • 9.3.2.2.5. By Factors
      • 9.3.2.2.6. By Route of Administration
      • 9.3.2.2.7. By Distribution channel
  • 9.3.3. South Africa Liver Cancer Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Type
      • 9.3.3.2.2. By Therapy
      • 9.3.3.2.3. By Equipment
      • 9.3.3.2.4. By Age
      • 9.3.3.2.5. By Factors
      • 9.3.3.2.6. By Route of Administration
      • 9.3.3.2.7. By Distribution channel

10. South America Liver Cancer Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cancer Type
  • 10.2.2. By Therapy
  • 10.2.3. By Equipment
  • 10.2.4. By Age
  • 10.2.5. By Factors
  • 10.2.6. By Route of Administration
  • 10.2.7. By Distribution channel
  • 10.2.8. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Liver Cancer Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cancer Type
      • 10.3.1.2.2. By Therapy
      • 10.3.1.2.3. By Equipment
      • 10.3.1.2.4. By Age
      • 10.3.1.2.5. By Factors
      • 10.3.1.2.6. By Route of Administration
      • 10.3.1.2.7. By Distribution channel
  • 10.3.2. Colombia Liver Cancer Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cancer Type
      • 10.3.2.2.2. By Therapy
      • 10.3.2.2.3. By Equipment
      • 10.3.2.2.4. By Age
      • 10.3.2.2.5. By Factors
      • 10.3.2.2.6. By Route of Administration
      • 10.3.2.2.7. By Distribution channel
  • 10.3.3. Argentina Liver Cancer Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cancer Type
      • 10.3.3.2.2. By Therapy
      • 10.3.3.2.3. By Equipment
      • 10.3.3.2.4. By Age
      • 10.3.3.2.5. By Factors
      • 10.3.3.2.6. By Route of Administration
      • 10.3.3.2.7. By Distribution channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Liver Cancer Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bayer AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bristol Myers Squibb
• 15.3. Merck & Co., Inc.
• 15.4. Exelixis, Inc.
• 15.5. Eisai Co., Ltd.
• 15.6. F. Hoffmann-La Roche Ltd
• 15.7. Pfizer Inc.
• 15.8. Eli Lilly and Company
• 15.9. Novartis AG
• 15.10. AstraZeneca PLC

16. Strategic Recommendations

17. About Us & Disclaimer